|
Poster Presentation at the ASCP Annual Meeting
|
1 June 2023 at 9:40am
|
|
Corporate Presentation - May 2023
|
23 May 2023 at 9:50am
|
|
BNO announces establishment of At-The-Market Equity Program
|
8 May 2023 at 9:15am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report Mar 2023
|
28 April 2023 at 4:55pm
|
|
Enrolment in Ph2b ATTUNE Clinical Trial of BNC210 completed
|
27 April 2023 at 4:40pm
|
|
Change in substantial holding
|
11 April 2023 at 2:30pm
|
|
Change in substantial holding
|
11 April 2023 at 2:10pm
|
|
Change in substantial holding
|
20 March 2023 at 6:35pm
|
|
Response to ASX Aware Query
|
14 March 2023 at 10:30am
|
|
Response to ASX Price Query
|
9 March 2023 at 3:10pm
|
|
PREVAIL Data Disclosure Presentation
|
9 March 2023 at 11:00am
|
|
Pause in Trading
|
9 March 2023 at 10:55am
|
|
Follow-up Analysis from PREVAIL Phase 2 Study of BNC210 in S
|
9 March 2023 at 10:45am
|
|
Trading Halt
|
8 March 2023 at 12:25pm
|
|
Pause in Trading
|
8 March 2023 at 11:10am
|
|
Notification regarding unquoted securities - BNO
|
23 February 2023 at 7:40pm
|
|
Notification of cessation of securities - BNO
|
23 February 2023 at 7:05pm
|
|
Cleansing Notice
|
23 February 2023 at 6:35pm
|
|
Change of Director's Interest Notice - SP
|
23 February 2023 at 6:30pm
|
|
Change of Director's Interest Notice - EDS
|
23 February 2023 at 6:20pm
|
|
Half Yearly Report and Accounts
|
23 February 2023 at 1:00pm
|
|
EGM Results of Meeting
|
21 February 2023 at 12:25pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 January 2023 at 5:20pm
|
|
Notice of General Meeting/Proxy Form
|
18 January 2023 at 9:50am
|
|
Notification of cessation of securities - BNO
|
9 January 2023 at 1:15pm
|
|
Initial Director's Interest Notice S. Papapetropoulos
|
9 January 2023 at 1:10pm
|
|
BNO Reports Topline Results in PREVAIL Phase2 Study BNC210
|
19 December 2022 at 10:25am
|
|
Proposed issue of securities - BNO
|
16 December 2022 at 3:45pm
|
|
BNO appoints Dr. Spyros Papapetropoulos as President and CEO
|
16 December 2022 at 9:45am
|
|
Change of Director's Interest Notice DW
|
28 November 2022 at 6:59pm
|
|
Change of Director's Interest Notice EDS
|
28 November 2022 at 6:59pm
|
|
Change of Director's Interest Notice AF
|
28 November 2022 at 6:55pm
|
|
Notification of cessation of securities - BNO
|
28 November 2022 at 6:45pm
|
|
Change in substantial holding
|
23 November 2022 at 2:50pm
|
|
Change in substantial holding
|
23 November 2022 at 10:55am
|
|
Cleansing Notice
|
22 November 2022 at 6:59pm
|
|
BNO Announces Closure of US$5m Offering in the US
|
22 November 2022 at 9:40am
|
|
Application for quotation of securities - BNO
|
21 November 2022 at 12:10pm
|
|
F1 Registration Filing for securities to be issued in the US
|
17 November 2022 at 2:15pm
|
|
Proposed issue of securities - BNO
|
17 November 2022 at 10:50am
|
|
BNO Announces Pricing of Underwritten Offering of ADS
|
17 November 2022 at 10:30am
|
|
2022 AGM Results of Meeting
|
16 November 2022 at 3:10pm
|
|
2022 AGM Executive Chairman's Presentation
|
16 November 2022 at 10:25am
|
|
Corporate Presentation - November 2022
|
15 November 2022 at 10:20am
|
|
Proposed Underwritten Offering of ADS's in the US
|
15 November 2022 at 10:20am
|
|
Amendment of Form F-1 for Proposed Offering of ADS's in US
|
15 November 2022 at 10:20am
|
|
Trading Halt
|
15 November 2022 at 9:55am
|
|
Filing of Form F-1 for Proposed Offering of ADS's in the US
|
11 November 2022 at 10:50am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
25 October 2022 at 10:15am
|
|
R&D tax incentive refund for FY2022 received
|
18 October 2022 at 9:35am
|
Bionomics